Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-10-21

Clinical Trial Update: Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and efficacy of ILV-094 in rheumatoid arthritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ILV-094 (ILV-094)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2022-10-21